Factor VIIa-CTP is a novel, long-acting recombinant Factor VIIa intended to be used to treat and to prevent bleeding episodes in hemophilia A or B patients. This molecule utilizes CTP technology to extend the circulatory half-life and significantly improves the treatment of hemophilia patients by reducing the frequency of rFVIIa infusions and by enabling prophylactic treatment.
Factor VIIa-CTP has been granted orphan drug designation in the U.S. and Europe.